{"id":19299,"date":"2023-04-25T16:17:00","date_gmt":"2023-04-25T08:17:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19299"},"modified":"2024-12-22T16:20:32","modified_gmt":"2024-12-22T08:20:32","slug":"luzhu-biotech-prepares-for-hkd-433-million-ipo-with-focus-on-vaccines-and-biologics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19299","title":{"rendered":"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics"},"content":{"rendered":"\n<p>Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million).<\/p>\n\n\n\n<p><strong>Company Background and Product Pipeline<\/strong><br>Founded in 2001, Luzhu Bio boasts a robust product pipeline that includes human vaccines, monoclonal antibodies (mAbs), and bispecific antibodies (BsAbs). The company currently has three clinical-stage product candidates: the vaccine candidate LZ901 and two antibody injection products, K3 and K193.<\/p>\n\n\n\n<p><strong>LZ901: A Promising Recombinant Shingles Vaccine<\/strong><br>The core product candidate, LZ901, is an in-house developed recombinant shingles vaccine used to prevent herpes zoster caused by the varicella zoster virus (VZV) in adults aged 50 and above. It is anticipated to become the world&#8217;s first tetramer molecular structure-based vaccine of its kind. Preclinical studies have demonstrated LZ901&#8217;s high immunogenicity, efficacy, and safety, with the ability to induce specific humoral and cellular immunity. Phase I clinical trial data from China show no significant difference in anti-VZV antibody levels between LZ901 and GlaxoSmithKline\u2019s Shingrix, suggesting that LZ901&#8217;s immunogenicity is comparable to Shingrix.<\/p>\n\n\n\n<p><strong>K3: A Biosimilar Version of Humira (Adalimumab)<\/strong><br>Another core product, K3, is a biosimilar version of Humira (adalimumab), which has completed Phase I trials. Expected to receive marketing approval in China by 2025, K3 was acquired by Luzhu Bio from Science Sun in July 2019 through an asset and intellectual property transfer deal.<\/p>\n\n\n\n<p><strong>K193: A Bispecific Antibody for B-Cell Leukemia and Lymphoma<\/strong><br>K193, a bispecific antibody (BsAb) targeting B-cell leukemia and lymphoma, has initiated Phase I clinical studies in China, with expectations to conclude in the second quarter of this year.<\/p>\n\n\n\n<p><strong>Additional Pipeline Developments<\/strong><br>Luzhu Bio is also developing a recombinant RVG subunit rabies vaccine, a recombinant varicella vaccine (adjusted dosage form of LZ901), CD33\/CD3 BsAb K333, and CD19\/CD3 BsAb K1932, further expanding its presence in the vaccine and biologics market.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,1641,28,12],"class_list":["post-19299","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ipo","tag-luzhu-biotechnology","tag-multi-specific-antibodies","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19299\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19299\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T08:17:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-22T08:20:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19299#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19299\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics\",\"datePublished\":\"2023-04-25T08:17:00+00:00\",\"dateModified\":\"2024-12-22T08:20:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19299\"},\"wordCount\":336,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"IPO\",\"Luzhu Biotechnology\",\"Multi-specific antibodies\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19299#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19299\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19299\",\"name\":\"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-25T08:17:00+00:00\",\"dateModified\":\"2024-12-22T08:20:32+00:00\",\"description\":\"Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19299#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19299\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19299#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19299","og_locale":"en_US","og_type":"article","og_title":"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19299","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-25T08:17:00+00:00","article_modified_time":"2024-12-22T08:20:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19299#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19299"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics","datePublished":"2023-04-25T08:17:00+00:00","dateModified":"2024-12-22T08:20:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19299"},"wordCount":336,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["IPO","Luzhu Biotechnology","Multi-specific antibodies","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19299#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19299","url":"https:\/\/flcube.com\/?p=19299","name":"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-25T08:17:00+00:00","dateModified":"2024-12-22T08:20:32+00:00","description":"Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19299#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19299"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19299#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19299"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19299\/revisions"}],"predecessor-version":[{"id":19300,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19299\/revisions\/19300"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}